Enclomiphene vs. TRT: The Fertility Question Nobody Asks Until It's Too Late

Most men come to this comparison having already decided something is wrong. The labs came back low. The fatigue, the flat mood, the training that stopped producing results — there's finally a number attached to it.

Then somewhere in the reading, a sentence stops them: testosterone therapy suppresses sperm production.

For a 30-year-old who hasn't started a family, or a 41-year-old on a second marriage, that changes the entire question. It stops being "which treatment raises testosterone" and becomes "which one raises testosterone without closing a door I might want open."

That's the real decision, and it turns on a piece of physiology worth understanding before you choose.

The system you're intervening in

Testosterone production runs on a feedback loop called the hypothalamic-pituitary-gonadal axis. Three organs, one conversation.

The hypothalamus releases gonadotropin-releasing hormone in pulses. That tells the pituitary to release two hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH travels to the Leydig cells in the testes and tells them to produce testosterone. FSH acts on the Sertoli cells and supports sperm production.

Then the loop closes. Testosterone — and estradiol converted from it — travels back to the hypothalamus and pituitary and signals that levels are adequate, which dials the whole cascade down. It's a thermostat.

One detail explains nearly everything below. Sperm production doesn't depend on the testosterone in your bloodstream. It depends on testosterone concentration inside the testes — intratesticular testosterone, which sits on the order of 50 to 100 times the level found in blood. Spermatogenesis requires that enormous local concentration. And the only thing that maintains it is LH signaling the Leydig cells directly.

So a treatment that raises blood testosterone while shutting off LH raises the number on your lab report and collapses the concentration where sperm are actually made.

The distinction that decides your options

Before comparing treatments, one question has to be answered, because it determines whether enclomiphene can work for you at all.

Is your low testosterone primary or secondary?

Primary hypogonadism means the testes themselves aren't producing, despite being told to. The pituitary is shouting — LH and FSH come back high — and the testes can't respond. Causes include Klinefelter syndrome, prior orchitis, testicular injury, chemotherapy, or age-related Leydig cell decline.

Secondary hypogonadism means the signal is the problem. The testes are capable, but the hypothalamus and pituitary aren't sending enough instruction. LH and FSH come back low or inappropriately normal alongside low testosterone. Common drivers: obesity and insulin resistance (adipose tissue converts testosterone to estradiol, which suppresses the axis harder), obstructive sleep apnea, opioid use, chronic stress, prior anabolic steroid use, and pituitary problems.

This matters enormously: enclomiphene works by amplifying a signal. If the testes can't respond to the signal, amplifying it does nothing. Enclomiphene is a treatment for secondary hypogonadism. In primary testicular failure, it's the wrong drug.

You cannot tell these apart by symptoms. It takes LH and FSH drawn alongside testosterone. Any evaluation that measures total testosterone and stops has skipped the step that determines your treatment options.

And before either treatment, the low reading itself has to be confirmed. Testosterone follows a daily rhythm, peaking in the morning and drifting down through the day, and it's suppressed by acute illness, poor sleep, and overtraining. Guidelines call for two separate morning measurements before diagnosing hypogonadism. An afternoon draw is uninterpretable. A single low morning draw isn't a diagnosis.

What TRT does

Testosterone replacement supplies the hormone from outside — injection, gel, pellet, or patch.

It works, and it works reliably. Blood levels rise, and for most men with genuine hypogonadism, symptoms follow: energy, mood, libido, body composition, bone density. It's the more predictable of the two options and it works regardless of whether your hypogonadism is primary or secondary, because it bypasses the broken part of the system entirely.

And that bypass is the cost. Your thermostat reads the incoming testosterone as evidence that levels are more than adequate. GnRH pulses slow. LH and FSH fall, often to near-undetectable. The Leydig cells stop being told to produce, intratesticular testosterone collapses, and spermatogenesis winds down.

In practice: most men on testosterone monotherapy develop severe oligospermia or azoospermia — no measurable sperm — typically within a few months. This effect is reliable enough that exogenous testosterone has been studied for decades as a male contraceptive. That's not a side effect discovered by accident; it's a well-characterized primary action.

Testicular volume usually decreases as well, for the same reason.

Is it reversible? Usually. Pooled data from the male contraceptive trials — healthy men, defined exposure — showed most recovering sperm production within about six months of stopping, roughly 90% within a year, and nearly all by two years.

Two caveats deserve weight. Those trials studied healthy young men with normal baseline fertility on time-limited protocols; they are not a clean model for a 45-year-old with pre-existing hypogonadism who has been on testosterone for six years. And "nearly all" is not all — persistent azoospermia after stopping does occur, and there is no reliable way to predict who.

If fertility matters to you at all, think of TRT as a decision with a recovery period you don't control and a small chance you don't get the outcome you want.

What enclomiphene does

Enclomiphene takes the opposite approach: rather than replacing the hormone, it removes the brake on your own production.

It's a selective estrogen receptor modulator. At the hypothalamus and pituitary, it blocks estrogen receptors — which is where the negative feedback signal lands. With that feedback interrupted, the brain reads the situation as testosterone being insufficient and responds by increasing GnRH, and therefore LH and FSH.

More LH means the Leydig cells are told to work harder, and blood testosterone rises. Crucially, it rises through the normal pathway — which means intratesticular testosterone stays high and FSH keeps supporting the Sertoli cells. Sperm production is maintained.

That's the entire case for enclomiphene: it raises testosterone using your own machinery, so the machinery keeps running.

Why enclomiphene rather than clomiphene? Clomiphene citrate — approved for female infertility and used off-label in men for years — is a mixture of two isomers. Enclomiphene is the trans-isomer: shorter-acting, and the one responsible for the anti-estrogenic effect at the pituitary that drives the benefit. Zuclomiphene is the cis-isomer: much longer half-life, more estrogenic in character, and it accumulates over weeks of daily dosing. The theory behind isolating enclomiphene is that you keep the mechanism you want and drop the isomer implicated in the mood changes, visual disturbances, and estrogenic side effects some men experience on clomiphene.

It's a reasonable theory with supportive data. It's worth knowing that clomiphene actually has the longer clinical track record in men, simply because it's been used off-label for far longer.

What the trials showed. Enclomiphene was developed by Repros Therapeutics and taken through Phase 3. The core finding held up: enclomiphene raised total testosterone into the normal range in men with secondary hypogonadism, comparably to topical testosterone — while maintaining sperm concentration, where the topical testosterone arm reduced it. The mechanistic promise was demonstrated.

The FDA status, stated plainly

Enclomiphene has never been approved by the FDA.

Repros submitted a New Drug Application for Androxal in early 2015 and received a Complete Response Letter on December 1, 2015. The agency's position was that the Phase 3 design was no longer adequate to demonstrate clinical benefit, and it raised concerns about study entry criteria, titration, and bioanalytical method validation. Notably, the objection was less about whether testosterone rose and more about whether raising it, on its own, constituted a demonstrated clinical benefit. No company has resubmitted since.

So every enclomiphene prescription written in the United States today is for a compounded preparation. It has no approved label, no REMS, and no mandatory post-market safety surveillance. Long-term safety data in men is thin — the exposure base is real-world use, not controlled follow-up.

Its regulatory footing is meaningfully firmer than that of the peptides currently working through FDA rulemaking, since clomiphene citrate is an approved drug and enclomiphene is one of its two isomers. But "more defensible than a peptide in limbo" is not the same as approved, and anyone prescribing or taking it should know exactly which basis their pharmacy is compounding under.

Anyone who tells you enclomiphene is FDA-approved is either misinformed or hoping you are.

Side by side

The third option worth knowing

hCG mimics LH directly, stimulating the Leydig cells and maintaining intratesticular testosterone. It's used alone, and it's also added alongside TRT specifically to preserve fertility and testicular volume while on testosterone — a combination many fertility-aware clinicians favor.

Two things to know. hCG is FDA-approved, with an indication that includes hypogonadotropic hypogonadism in males — which distinguishes it from enclomiphene. But under the biologics transition that took effect March 23, 2020, hCG was reclassified as a biological product, and compounding pharmacies can no longer produce it under 503A or 503B. Only FDA-approved product is available, and supply has been inconsistent.

It's injectable rather than oral, which matters to some men and not others.

What the evidence says about TRT itself

Worth separating from the fertility question, because TRT carries baggage that recent data has partly resolved.

For years, cardiovascular safety was unsettled. TRAVERSE addressed it directly: 5,246 men aged 45–80 with pre-existing or high cardiovascular risk and confirmed hypogonadal symptoms, randomized to transdermal testosterone or placebo, treated for a mean of 21.7 months and followed for a mean of 33 months. Testosterone was non-inferior to placebo for major adverse cardiac events. That's a meaningful reassurance in exactly the population where the concern was highest.

It was not entirely clean. Several secondary signals appeared more often in the testosterone group: atrial fibrillation (91 vs. 63 cases), acute kidney injury (60 vs. 40), pulmonary embolism, and — in a separate analysis of the same trial — a numerically higher fracture rate (3.5% vs. 2.5%). These hadn't been flagged in earlier randomized trials and remain under investigation.

The reasonable read: in men with genuine, confirmed hypogonadism, TRT does not appear to carry the cardiovascular risk once feared — and it still requires real monitoring rather than a refill button.

Which one fits

Enclomiphene is worth considering if:

• Your hypogonadism is secondary — low or normal LH/FSH with low testosterone
• Fertility matters now or might later
• You'd rather not commit to indefinite exogenous hormone
• You want to preserve testicular function and volume
• You'd prefer a daily tablet to injections
• You're comfortable with a compounded, non-FDA-approved medication

TRT is likely the better fit if:

• Your hypogonadism is primary — high LH/FSH — where enclomiphene won't work
• Your family is complete, or fertility genuinely isn't a consideration
• You've tried enclomiphene without adequate response
• You want the more predictable, better-characterized option with decades of data behind it
• Symptoms are severe enough that reliability outweighs preserving the axis

A note on sequence that a lot of men wish they'd heard first: if you're uncertain about fertility, starting with enclomiphene is the reversible order of operations. It preserves the option. Going the other way — starting TRT and then trying to restore fertility — means a restart protocol, months of waiting, and an outcome nobody can promise you.

And treat the underlying cause either way. A meaningful share of secondary hypogonadism in men under 50 is driven by things that respond to treatment: visceral adiposity, untreated sleep apnea, opioids, chronic sleep restriction. Adipose tissue converts testosterone to estradiol, which suppresses the axis, which lowers testosterone, which makes fat loss harder — a loop worth breaking directly rather than only medicating around. Men who address those causes sometimes need less treatment than they expected, or none.

Monitoring, whichever you choose

Neither of these is a set-and-forget subscription.

On enclomiphene: total and free testosterone, LH, FSH, and estradiol; a semen analysis if fertility is an active goal; and attention to visual disturbances or mood changes, which are recognized SERM class effects.

On TRT: total and free testosterone, hematocrit — erythrocytosis is the most common clinically relevant adverse effect and requires monitoring — estradiol, PSA where age-appropriate, and lipids. Plus symptoms.

For both: a baseline picture of metabolic health, because hypogonadism and metabolic dysfunction travel together and treating one without seeing the other is half a job. The markers worth having are in 5 Biomarkers Everyone Should Track After 30.

The bottom line

These aren't competing versions of the same treatment. TRT replaces a hormone. Enclomiphene restarts the signal that produces it. That difference determines what happens to your fertility, your testicular function, and how reversible the decision is.

If your hypogonadism is secondary and fertility is anywhere in your thinking — now or in a decade — enclomiphene preserves optionality that TRT spends. If your hypogonadism is primary, or your family is complete, TRT is the more proven and predictable option and the fertility question is moot.

What shouldn't happen is choosing without knowing which kind of hypogonadism you have. That takes LH and FSH alongside two morning testosterone measurements — and it's the step most likely to be skipped by a service optimized to get you to checkout.

Your reserve is the capacity you keep in hand for later — including the capacity to change your mind. This is one of the few clinical decisions where preserving that option costs almost nothing, as long as you make it in the right order.

---

Frequently asked questions

Will TRT make me permanently infertile? Usually not. Most men recover sperm production within about six months of stopping and roughly 90% within a year. But recovery isn't guaranteed, it isn't fast, and it can't be predicted in advance. If fertility matters, factor that in before starting rather than after.

Is enclomiphene FDA-approved? No. Its only New Drug Application received a Complete Response Letter in December 2015, and no company has resubmitted. All enclomiphene in the US is compounded.

Can I take enclomiphene while on TRT? It doesn't work that way — exogenous testosterone suppresses the axis enclomiphene acts on. hCG is the agent typically added alongside TRT to preserve fertility and testicular volume.

How long until enclomiphene works? Testosterone usually rises within a few weeks. Symptom improvement takes longer — generally give it about three months, with labs along the way.

What if enclomiphene doesn't raise my testosterone? That usually means the testes have limited capacity to respond — pointing toward primary hypogonadism, where TRT is the appropriate option. It's useful information, not a wasted trial.

Does enclomiphene work for men over 50? It can, if the hypogonadism is secondary. Age-related decline often involves some primary component, so response tends to be less predictable — which is exactly why LH and FSH need measuring first.